9688 Stock Overview
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9688 from our risk checks.
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.00 |
| 52 Week High | US$29.50 |
| 52 Week Low | US$10.56 |
| Beta | 1.12 |
| 1 Month Change | 0.78% |
| 3 Month Change | -25.29% |
| 1 Year Change | -49.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9688 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 5.0% | 4.3% | 2.6% |
| 1Y | -49.6% | -37.2% | -7.4% |
Return vs Industry: 9688 underperformed the Hong Kong Biotechs industry which returned -37.6% over the past year.
Return vs Market: 9688 underperformed the Hong Kong Market which returned -8.5% over the past year.
Price Volatility
| 9688 volatility | |
|---|---|
| 9688 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 9688's share price has been volatile over the past 3 months.
Volatility Over Time: 9688's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| 9688 fundamental statistics | |
|---|---|
| Market cap | HK$12.20b |
| Earnings (TTM) | -HK$2.62b |
| Revenue (TTM) | HK$2.09b |
5.8x
P/S Ratio-4.7x
P/E RatioIs 9688 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9688 income statement (TTM) | |
|---|---|
| Revenue | US$266.72m |
| Cost of Revenue | US$361.68m |
| Gross Profit | -US$94.96m |
| Other Expenses | US$239.66m |
| Earnings | -US$334.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -3.39 |
| Gross Margin | -35.60% |
| Net Profit Margin | -125.46% |
| Debt/Equity Ratio | 0% |
How did 9688 perform over the long term?
See historical performance and comparison